FLUARIX
Description
FLUARIX® is a split virion (split virus) inactivated Influenza vaccine. The virus is concentrated, inactivated and “split” by disrupting its membranes from Influenza viruses propagated in embryonated chicken eggs. FLUARIX is a vaccine indicated for active immunization for the prevention of disease caused by Influenza A subtype viruses and type B virus contained in the vaccine. FLUARIX is approved for use in persons 3 years of age and older.
- A/Christchurch/16/2010 NIB 74 XP (H1N1) (an A/California/7/ 2009-like virus)
- A/Switzerland/9715293/ 2013 NIB-88 (H3N2)
- B/Phuket/ 3073/2013
Immunization Guideline:
Children 3 through 8 years of age who are not previously vaccinated with influenza vaccine should receive two doses (0.5-mL each) at least 4 weeks apart. Children vaccinated with influenza vaccine in a previous season should receive one or two doses of 0.5-mL each (2 doses at an interval of 4 weeks).
9 years of age and older can receive one 0.5-mL dose.
Additional information
manufacturer | GlaxoSmithKline |
---|---|
country-of-manufacture | Germany |
vaccine-type | Influenza |
pharmaceutical-form | Liquid |
package-size | 1 Dose |
route-of-administration | Intramuscular |
preservative | None |
Contraindications | Do not administer FLUARIX to anyone with a history of severe allergic reactions (e.g.anaphylaxis) to any component of the vaccine,including egg protein, or following a previous administration of any influenza vaccine. |